Cevitas' inhaler delivers Levodopa to PD patients experiencing "off episodes."

Cynapsus (which I own) has something potentially better than that - CYNAF's rescue treatment is a dissolvable strip placed under the tongue. "APL-130277 [is] an easy-to-administer and fast-acting reformulation of apomorphine, which is used to rescue patients from off episodes." Since patients experiencing off- episodes are usually unable to handle a syringe they need a simpler method of delivery such as a sublingual strip. Or they have to rely on a caregiver.

When AMBS has the cash it would be nice to see them scoop up some companies like Cynapsus which has a 44m mkt cap.

Quote:

---

Napodano on twitter: - @pbmech If Civitas is worth $525M, then Cynapsus is going to be worth at least that much in 12 months, probably more. $CYNAF

---

Herantis Pharma could be another interesting acquisition for AMBS. They own CDNF, trade on the Nordic NSDQ exchange and have roughly 50m (U.S.) mkt cap.